Marshall Wace
SRPT icon

Marshall Wace’s Sarepta Therapeutics SRPT Stock Holding History

Marshall Wace’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-210,000
Closed -$8.96M – 1107
2016
Q3 		$8.96M Buy
+210,000
New +$6.35M 0.06% 305

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace's SRPT Position: Q1 2026 in Review

Marshall Wace increased its Sarepta Therapeutics (SRPT) stake by 405% in Q1 2026, buying an estimated $11.3M and bringing the position to 725,068 shares worth $15.8M. The position accounts for 0.02% of the portfolio, ranked #786.

Marshall Wace first reported a position in SRPT in Q1 2015 and has held it in 23 quarters since. The position peaked at $45.4M in Q4 2021. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Marshall Wace held 725,068 shares of Sarepta Therapeutics worth $15.8M as of Q1 2026.
  • Marshall Wace bought 581,575 Sarepta Therapeutics shares in Q1 2026, an estimated $11.3M.
  • Sarepta Therapeutics made up 0.02% of Marshall Wace's portfolio in Q1 2026, its #786 holding.
  • Marshall Wace first reported a position in Sarepta Therapeutics in Q1 2015 and has held it in 23 quarters since.
  • Marshall Wace's Sarepta Therapeutics position peaked at $45.4M in Q4 2021.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.